08 September 2020>: Clinical Research
Serum-Soluble ST2 Is a Novel Biomarker for Evaluating Left Atrial Low-Voltage Zone in Paroxysmal Atrial Fibrillation
Zefeng Wang 1ACDE , Liting Cheng 1BCD , Junmeng Zhang 1AD , Zhuo Liang 1CD , Ruiqing Dong 2B , Fei Hang 1B , Xinlu Wang 1B , Ziyu Wang 1B , Yongquan Wu 1AD* , Jie Du 3ADE*DOI: 10.12659/MSM.926221
Med Sci Monit 2020; 26:e926221
Table 1 Comparison of baseline clinical materials.
Group A (n=125) | Group B (n=52) | P valve | |
---|---|---|---|
Age, y | 56.4±9.4 | 62.4±9.3 | 0.002 |
Male, n (%) | 87 (69.6%) | 36 (69.2%) | 0.961 |
BMI, kg/m | 31.4±7.0 | 32.3±8.7 | 0.501 |
AF duration, y | 24 (12, 48) | 24 (12, 48) | 0.789 |
Hypertension, n (%) | 70 (56.0%) | 27 (51.9%) | 0.620 |
Diabetes, n (%) | 24 (19.2%) | 8 (6.4%) | 0.548 |
CHD, n (%) | 16 (12.8%) | 3 (5.8%) | 0.169 |
ALT, U/L | 23.9±10.2 | 25.9±10.2 | 0.646 |
AST, U/L | 24.1±8.7 | 22.7±5.8 | 0.284 |
eGFR | 92.0±18.4 | 98.2±19.1 | 0.046 |
CREA, mol/L | 72.0±16.8 | 69.1±14.8 | 0.272 |
UA, mol/L | 343.4±100.9 | 340.7±92.0 | 0.865 |
GLU, mmol/L | 5.9±1.6 | 5.2±0.8 | 0.093 |
TCHO, mmol/L | 4.7±1.7 | 4.6±1.2 | 0.682 |
LDL, mmol/L | 2.9±1.0 | 2.9±1.0 | 0.888 |
HDL, mmol/L | 1.2±0.2 | 1.1±0.3 | 0.278 |
TG, mmol/L | 1.8±1.1 | 1.7±0.9 | 0.494 |
hs CRP, mg/L | 0.9 (0.6,2.1) | 1.0 (0.6,2.0) | 0.964 |
LAAP-diameter, mm | 40.4±5.1 | 41.6±5.0 | 0.157 |
EF,% | 61.6±6.0 | 60.3±5.5 | 0.078 |
Normally distributed continuous variables are expressed as mean±standard deviation; non-uniformly distributed data are expressed as median (Q1, Q3); numbers are presented as number of patients (%). BMI – body mass index; AF – atrial fibrillation; CHD – coronary heart disease; ALT – alanine transaminase; AST – aspartate aminotransferase; eGFR – estimated glomerular filtration rate; CREA – creatinine; UA – uric acid; GLU – glucose; TCHO – total cholesterol; LDL – low-density lipoprotein; HDL – high-density lipoprotein; TG – triglyceride; LAAP-diameter – left atrial anteroposterior diameter; EF – ejection fraction. |